mar feb jan dec nov oct sep i'm a bit behind on listing relevant fda update info , so i 'll get you all up to date zyprexa olanzapine labeling change label was revised to state that rare postmarketing reports of hepatitis have been received very rare cases of cholestatic or mixed liver injury have also been reported in the postmarketing period pdf bifeprunox for schizophrenia phase iii results were released showing that patients did better on this than on placebo over months not hard to beat placebo they also reported weight and lipid profile reductions their new drug application was submitted to the fda in october invega iloperidone results these results are interesting in that they looked at efficacy and side effects data stratified by whether or not one had a particular pharmacogenetic genotype they do not identify the genotype , but i suspect it is something like drd or dat so far , however , we have yet to see the promise of a pharmacogenetic test which one would perform prior to prescribing a drug for this to really work , the test will have to be free and the results available promptly melt in your mouth methadone roxane got a dissolvable mg methadone approved invega iloperidone approved this is an active metabolite of risperdal risperidone , very similar to this atypical antipsychotic label detailed review